Varicose Veins Treatment Market Trends

Growth Drivers

• Improved healthcare and cost-effective interventions: The implementation of sclerotherapy as an early-stage detection strategy has the capability to diminish hospitalization requirements. According to a 2022 AHRQ study, it was found that foam-based sclerotherapy for early-stage varicose veins usually reduces hospitalization rates by almost 28.5%, which eventually results in a saving of USD 450.8 million for almost next two years. Besides, the implementation of artificial intelligence as an effective intervention has the ability to improve treatment accuracy by reducing repetitive procedures by 21%, thus driving the market globally.

• Rising age population and disease prevalence: This is another growth factor that positively impacts the overall market across different nations. For instance, in Europe and North America, an estimated 31% of the total adult population readily suffers from venous insufficiency, thus driving the market demand in both these regions. In addition, the prevalence of the disorder in Germany increased to 13 million in 2024, which accounts for a 26% rise since previous years. Besides, on a global basis, the geriatric population, that over 65 years of age, accounts for almost 46% of varicose veins treatment demand in Europe, thus a positive outlook for the overall market.

Market Expansion Through Historical Patient Growth Analysis

The international varicose veins treatment market is shaped by factors such as extended insurance coverage, advanced diagnostic rates, and demographic modifications between 2014 and 2024. The patient pool in developed nations such as Germany and the U.S., experienced steady growth owing to the increased awareness of minimally invasive treatment procedures and a surge in the aging population. Besides, there has been Medicare expansion in the U.S. for certain therapies, ensuring an estimated 58.5% increase among aided patients. In addition, France and Germany have also benefited from such health services with the implementation of ultrasound-specific procedures, thereby constituting a prolific opportunity for the market.

2014-2024 Historical Patient Growth Data

Key Manufacturing Strategies Driving Varicose Veins Treatment Market Expansion

Leading manufacturers of the market have extended their market positions through strategies such as geographic expansion, tactical partnerships, and product innovation. For instance, as stated in the U.S. FDA government report, Medtronic’s VenaSeal closure system grabbed an estimated 20.5% of the U.S. market in 2023 and generated USD 480.5 million in terms of revenue. Likewise, Boston Scientific acquired Veniti and expanded its radiofrequency ablation portfolio, which boosted its sales by 19% in the Europe market. Besides, emerging nations such as China and India observed the introduction of low-cost laser systems by Biolitec AG, which resulted in an increased penetration of 36%, thereby amplifying the overall market globally.

Revenue Opportunities for Manufacturers

Challenges

• Crisis in medical coverage: The presence of access-specific barriers in global healthcare and medical systems causes a hindrance in the varicose veins treatment market. According to an article published by the CMS in 2024, only 19 out of 50 state Medicaid programs in the U.S. tend to cover foam sclerotherapy, and only 7 get reimbursed for radiofrequency ablation. This results in an estimated 4.3 million Medicaid enrollees with symptomatic varicose veins treatment without any coverage, eventually resulting in 590,000 hospitalizations yearly at a cost of USD 2.2 billion.

• Affordability crisis in emerging markets: This is mainly observed across developing countries, wherein the treatment expense exceeds patients’ ability to make the treatment or diagnosis payment. For instance, India's National Health Profile stated that the average price of endovenous laser treatment is ₹85,000 per 1,020 patients, which accounts for USD 148,340 per unit. This, in turn, enables hospitals to provide complete treatment procedures at ₹45,000 (155 per unit), thus capturing almost 28.5% of the country’s private market in just two years.